Ketamine clinic marketing: FDA and ad rules

Ketamine clinics market to people who are often struggling, have tried other options and are searching for something that might help. That is exactly why the rules around ketamine marketing are strict, and why the most trusted clinics are careful about what they say.

This guide covers the facts and rules a clinic should build its marketing on: what FDA has and has not approved, the FDA warning about compounded and at-home ketamine, controlled substance and telemedicine rules, FTC rules for health claims and patient stories, privacy, ad platforms and crisis resources. It does not cover dosing, protocols, patient selection or whether ketamine is right for anyone. Those are clinical decisions for licensed providers.

This is general information, not legal or medical advice. Sources cited were checked on October 29, 2026: the FDA compounding risk alert of October 10, 2023 on compounded ketamine products for psychiatric disorders (read from the Internet Archive copy of May 30, 2026, because the FDA URL now returns page not found), 21 CFR 1308.13 (Schedule III), the Federal Register notice of December 31, 2025 extending DEA telemedicine flexibilities through December 31, 2026, the FTC Health Products Compliance Guidance, 16 CFR 255.2, 16 CFR Part 465, 45 CFR 164.508, the Google Ads Healthcare and medicines policy, Meta’s Drugs and Pharmaceuticals ad standard SAMHSA’s 988 page, and two current FDA documents: an FDA warning letter of June 23, 2026 (MARCS-CMS 725147) about online ketamine sales and the FDA-approved prescribing information for the esketamine nasal spray (revised January 2025). The telemedicine date may change before it ends. States regulate medical practice, telehealth and advertising in their own ways. Have a health care attorney review your marketing.

Get the FDA status right

Most ketamine marketing problems start with a single inaccurate phrase about FDA. The FDA’s October 10, 2023 compounding risk alert sets out the facts plainly:

Ketamine hydrochloride is a Schedule III controlled substance that is FDA approved as an intravenous or intramuscular injection for induction and maintenance of general anesthesia.
Ketamine is not FDA approved for the treatment of any psychiatric disorder. FDA says it has not determined that ketamine is safe and effective for uses such as depression, anxiety, PTSD or obsessive-compulsive disorder.
Esketamine, one of the two mirror-image molecules in ketamine, is FDA approved as a nasal spray for specific depression indications in adults, used with an oral antidepressant. It is available only under a Risk Evaluation and Mitigation Strategy (REMS).
Compounded drugs, including compounded ketamine, are not FDA approved and have no FDA-approved indications or routes of administration.

FDA has repeated these points in current documents. In a warning letter dated June 23, 2026 to a website selling ketamine, FDA again described FDA-approved ketamine as a Schedule III intravenous or intramuscular injection indicated as a general anesthetic, and said it has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. The letter cited the website’s own claim about pain relief, depression treatment and anxiety management as evidence that its product was a drug intended for human use. The current esketamine prescribing information, revised January 2025, states that the drug is available only through a restricted program under a REMS and that patients must be monitored by a health care provider for at least 2 hours at each treatment session.

For marketing, this means three things. Never describe ketamine as FDA approved for depression or any other psychiatric condition. Never borrow the esketamine approval to describe ketamine infusions; they are different products with different approval status. And if your clinic offers the approved esketamine nasal spray, describe it only in terms consistent with its labeling and REMS, and leave clinical detail to the consultation. Using the brand names of prescription drugs in ads brings separate platform rules, covered below.

The REMS and at-home ketamine

FDA’s alert explains that the esketamine REMS requires the drug to be dispensed and administered in medically supervised health care settings that are certified in the REMS and agree to monitor patients for a minimum of two hours after administration, because of possible sedation and dissociation and the potential for misuse and abuse.

The same alert warns that use of compounded ketamine products without monitoring by a health care provider for sedation, dissociation and changes in vital signs may put patients at risk for serious adverse events. FDA says it is aware of interest in at-home use of compounded sublingual and oral ketamine obtained through telemedicine platforms, that it has not established safe or effective dosing of ketamine for any psychiatric indication, and that it is not aware of evidence that compounded ketamine is safer, more effective or faster acting than FDA-approved medications for certain psychiatric disorders.

A clinic’s marketing should not contradict any of that. Ads promising fast relief, home kits with no monitoring, or results in a set number of sessions sit directly against FDA’s published concerns.

Schedule III and telemedicine

Ketamine, its salts, isomers and salts of isomers are listed in Schedule III under 21 CFR 1308.13, so prescribing and dispensing follow DEA controlled substance rules. For telehealth, the DEA and HHS issued a fourth temporary extension of the COVID-19 era telemedicine flexibilities for prescribing controlled medications, published in the Federal Register on December 31, 2025, running through December 31, 2026.

If your marketing mentions virtual visits, be precise about what happens virtually and what happens in person, and do not imply that controlled substances can be prescribed online indefinitely. That date may change, so review any telehealth wording before the end of 2026. Our guide to telehealth marketing for practices covers the wider rules.

Health claims and patient stories

The FTC Health Products Compliance Guidance says claims about the health benefits or safety of health-related products and services require competent and reliable scientific evidence, and that advertisers are responsible for implied claims as well as express ones. For ketamine, given FDA’s statements about its approval status, broad efficacy claims are very hard to support.

Do not claim that ketamine treats, cures or relieves depression, anxiety, PTSD, pain or any other condition.
Do not state response rates, speed of relief, number of sessions or how long effects last.
Do not describe ketamine as safe, safer or without side effects. FDA lists known concerns including abuse and misuse, psychiatric events, increased blood pressure, respiratory depression and bladder symptoms.
Describe what you do instead: who your providers are, how evaluation works, the setting, how monitoring works and what happens after a visit.

Patient stories carry extra weight here. Under 16 CFR 255.2(b), an ad that relates one patient’s experience on a key point is likely to be read as showing what patients will generally achieve, and without substantiation that it is representative, the ad should clearly disclose the generally expected results. For a treatment FDA has not approved for psychiatric use, that substantiation is unlikely to exist. Most clinics are better served by not using mental health outcome stories at all.

Mental health information and privacy

Information that someone sought ketamine treatment is sensitive health information. Under 45 CFR 164.508, using protected health information for marketing generally requires a written authorization meeting that section’s requirements. Be just as careful with online tracking on pages about mental health conditions; our guide to tracking pixels on practice websites explains the risks. Review replies should never confirm that someone is a patient, and 16 CFR Part 465 prohibits fake reviews and, in section 465.4, incentives conditioned on positive reviews.

Ad platform rules

Google’s Healthcare and medicines policy restricts the promotion of prescription drugs, and prescription drug terms in ads, landing pages and keywords. Meta’s Drugs and Pharmaceuticals ad standard requires telehealth providers promoting prescription drugs to show they are appropriately licensed, generally through LegitScript certification, and does not allow prescription drug targeting to people under 18. Plan any ketamine campaign around these policies before you build it; our Google Ads page explains how we work with restricted categories.

Crisis resources belong on the site

People who reach a ketamine clinic’s website may be in crisis. SAMHSA’s 988 Suicide and Crisis Lifeline page tells people in crisis to call or text 988. Put that information on every page where someone might look for help, make clear that your clinic is not an emergency service, and train staff and any automated assistant to point people to 988 or 911 rather than trying to handle a crisis themselves. An AI front desk should answer only general questions about the clinic and pass anything clinical or urgent to people.

What tends to work, inside the rules

Accurate service pages. What you offer, the FDA status of each product stated correctly, who provides it, and how evaluation and monitoring work.
Provider credentials. Real names, licenses and training, stated exactly, as covered on our integrative medicine marketing page.
Referral relationships. Many patients come from their own psychiatrists, therapists or physicians. Give referrers clear information about your process and how you communicate back.
Plain cost information. What a consultation and each visit cost, and what insurance does and does not cover, without promising coverage.
Crisis information everywhere. 988 and 911, clearly placed.

Is ketamine FDA approved for depression?

No. FDA’s October 10, 2023 alert says ketamine is not FDA approved for the treatment of any psychiatric disorder. Ketamine is approved as an injection for anesthesia. Esketamine, a related molecule, is approved as a nasal spray for specific depression indications in adults under a REMS.

Can we advertise at-home ketamine?

Be very careful. FDA has warned that compounded ketamine used without monitoring by a health care provider may put patients at risk, and that it has not established safe or effective dosing for any psychiatric indication. Telehealth prescribing of a Schedule III drug also depends on DEA rules currently extended through December 31, 2026.

Can we share patient success stories?

Only with written HIPAA authorization under 45 CFR 164.508, and under 16 CFR 255.2(b) a story is likely to be read as typical. Given FDA’s statements on ketamine’s status, substantiating typical results is very difficult, so many clinics avoid outcome stories.

Can we run Facebook ads for ketamine therapy?

Meta requires telehealth providers promoting prescription drugs to show appropriate licensing, generally through LegitScript certification, and does not allow prescription drug targeting to people under 18. Check the current policy before launching.

Do we need crisis information on our website?

It is strongly advisable. People in crisis may find your site. SAMHSA directs people in crisis to call or text 988, and your site should say your clinic is not an emergency service.

Sources

More in Mental and behavioral health marketing

Ketamine clinic marketing: FDA status, Schedule III, telehealth and ad rules